Clinical trials: Pioglitazone
Non-alcoholic Fatty Liver Disease NAFLD, Non-alcoholic Steatohepatitis NASH
Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease
The goal of this clinical trial is to assess the efficacy of Empagliflozin versus Statins as monotherapy and polytherapy in non-alcoholic fatty liver disease and non-alcoholic Steatohepatitis.
- Trial name
- NCT07180745
- Testing
- Pioglitazone (PIO), Empagliflozin, Statin (Atorvastatin)
- Where
- Egypt
- Volunteers
- 400 people
- Sponsor
- Badr University
Type 2 Diabetes
A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes
This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2…
- Trial name
- TELOS (NCT06972732)
- Testing
- Metformin, Dapagliflozin/Pioglitazone, Dapagliflozin/Sitagliptin
- Where
- South Korea
- Volunteers
- 204 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Type 1 Diabetes
Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?
Previous data from our clinical trial has demonstrated that the combination of dapagliflozin plus pioglitazone cause robust decrease in the plasma glucose concentration without significant increase in plasma ketone concentration…
- Trial name
- NCT06922656
- Testing
- Dapagliflozin (DAPA), Pioglitazone 45 mg
- Where
- 3 sites in Kuwait, Qatar and 1 more
- Volunteers
- 60 people
- Sponsor
- Dasman Diabetes Institute
Alcohol Use Disorder
Effects of Pioglitazone on Stress Reactivity and Alcohol Craving
The purpose of this study is to examine the effects of pioglitazone on stress-induced relapse risk in a laboratory model and to examine the effects of pioglitazone on drinking, stress/anxiety, and alcohol craving in the natural…
- Trial name
- NCT05107765
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- The University of Texas Health Science Center, Houston
Diabetic, Myocardial Infarction
The Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction in Diabetic Rats
The aim of the present study is to evaluate the prophylactic effect of Sitagliptin, Pioglitazone and Dapagliflozine on Isoprenaline induced myocardial infarction in type II diabetic rats.
- Trial name
- NCT07083232
- Testing
- standard normal diet, low dose Streptozotocin, Sitagliptin (Novartis, USA)
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Al-Azhar University
Diabetes Mellitus
A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)
This was an open-label, randomized, fasting, single-dose, 2-sequence, 2-period crossover study to evaluate the pharmacokinetics and safety between single oral administration of "BR3006" and co-administration of "BR3006A"…
- Trial name
- NCT07083388
- Testing
- Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg, Dapagliflozin 10 mg, Pioglitazone 30 mg
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diabete Mellitus
A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed)
This was an open-label, randomized, fed, single-dose, 2-sequence, 2- period crossover study to evaluate the pharmacokinetics and safety between single oral administration of "BR3006" and co-administration of "BR3006A", "BR3006B,"…
- Trial name
- NCT07083401
- Testing
- Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg, Dapagliflozin 10 mg, Pioglitazone 30 mg
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diabetes Mellitus Type 2
HbA1c Variability in Type II Diabetes
There are numerous possible reasons why it could be speculated that HbA1c variability may affect complication risk. Of interest are the concepts that both laboratory and clinic evidence suggests that periods of sustained…
- Trial name
- NCT02879409
- Testing
- Metformin, Gliclazide, Sitagliptin
- Where
- Qatar
- Volunteers
- 150 people
- Sponsor
- Weill Cornell Medical College in Qatar
Lung Cancer
The Neuroendocrine Effects of Pioglitazone in Patients With Cancer and Cachexia
The goal of this clinical trial is evaluate the effect of pioglitazone compared with placebo on skeletal muscle insulin sensitivity in subjects with cancer and cachexia.
- Trial name
- TRACE-1 (NCT05919147)
- Testing
- Pioglitazone 45 mg
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Pennington Biomedical Research Center
Type 2 Diabetes Mellitus
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients
This study is to evaluate the efficacy and safety after concomitant administration of ASP1941 and pioglitazone in patients with diabetes mellitus.
- Trial name
- NCT01225081
- Testing
- ipragliflozin, Pioglitazone
- Where
- 7 sites in Japan
- Volunteers
- 152 people
- Sponsor
- Astellas Pharma Inc
Type 2 Diabetes, Fatty Liver
Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes
This exploratory study will assess the efficacy of combined pioglitazone and empagliflozin therapy in improving hepatic and metabolic outcomes in patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty…
- Trial name
- NCT06989723
- Testing
- Pioglitazone 15 MG [Actos], Empagliflozin 10 MG [Jardiance], Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Seoul National University Bundang Hospital
Gastroparesis
Pioglitazone for Idiopathic Gastroparesis
The principal objective of this pilot study will be to evaluate whether 8 weeks of treatment of pioglitazone will improve symptoms as measured by the Gastrointestinal Symptom Index (GCSI) in patients with Idiopathic Gastroparesis.
- Trial name
- PIOGAS (NCT04300127)
- Testing
- Pioglitazone 30 mg
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Johns Hopkins University
Breast Cancer, Muscle Fatigue
Pioglitazone Therapy Targeting Fatigue in Breast Cancer
The goal of this project is to evaluate the therapeutic potential of pioglitazone (PIO) to target underlying mechanisms that promote muscle fatigue in patients with breast cancer.
- Trial name
- NCT05013255
- Testing
- Pioglitazone 15mg, Pioglitazone 30 mg
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- West Virginia University
Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Steatohepatitis
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT04501406
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 166 people
- Sponsor
- University of Florida
Leukemia, Chronic Myeloid
Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response
The purpose of this study is to evaluate treatment-free remission after imatinib discontinuation in patients with chronic myeloid leukemia with deep molecular response.
- Trial name
- EDI-PIO (NCT02852486)
- Testing
- Pioglitazone 30 Mg Oral Tablet, imatinib discontinuation
- Where
- Brazil
- Volunteers
- 31 people
- Sponsor
- University of Campinas, Brazil
Type2diabetes
Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control
In this study, we aim to explore the beneficial effect of early short-term (two weeks), self-titrated, basal-only insulin therapy on the degree of glycemic control over 1-year follow through a prospective cohort.
- Trial name
- NCT06107153
- Testing
- Insulin Glargine 100 UNT/ML Pen Injector [Lantus], Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg, Pioglitazone 30mg
- Where
- Iraq
- Volunteers
- 243 people
- Sponsor
- University of Basrah
Newly Diagnosed Type 2 Diabetes
Managing DIabetes Remission After Combined Therapy in EarLy Stage of DiabetEs
Epidemiologic, social and economic burdens of type 2 diabetes mellitus (T2DM) keep rising worldwide. Implementation of T2DM preventive trategies is lagging behind.
- Trial name
- MIRACLE (NCT04271189)
- Testing
- Metformin-Sitagliptin-Empaglifozin-Pioglitazone, Standard of care
- Where
- Italy
- Volunteers
- 108 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
COVID-19
The KIN-FAST Trial (KIN001 For Accelerated Symptoms Termination) in Non Hospitalized Patients Infected With SARS-CoV-2
Clinical trial on safety and efficacy of KIN001 in non-hospitalized patients with COVID-19.
- Trial name
- KIN-FAST (NCT05659459)
- Testing
- KIN001
- Where
- 8 sites in Germany, Switzerland
- Volunteers
- 17 people
- Sponsor
- Kinarus AG
Type 2 Diabetes Mellitus
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety and potential effectiveness of CCX140-B in subjects with Type 2 diabetes mellitus.
- Trial name
- NCT01028963
- Testing
- pioglitazone, CCX140-B
- Where
- 28 sites in Australia, Czechia and 3 more
- Volunteers
- 159 people
- Sponsor
- Amgen
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Type 2 Diabetes
Antidiabetic Drugs for Steatotic Liver Disease
To investigate the synergic therapeutic effect of thiazolidinediones and SGLT2 inhibitor on metabolic dysfunction-associated steatotic liver disease, the effect of empagliflozin 10mg, pioglitazone 15mg monotherapy and combination…
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Type 2 Diabetes, Digestive System Disease, Liver Diseases
- Trial name
- NCT03646292
- Testing
- Pioglitazone, Empagliflozin, Combination of pioglitazone and empagliflozin
- Where
- South Korea
- Volunteers
- 51 people
- Sponsor
- Yonsei University